NanoString Technologies, Inc. ... Upcoming launch of CosMx 6,000-plex assay. NanoString also remains on track to begin commercial shipment of the CosMx Human 6K Discovery Panel beginning in Q1 2024.

NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the commercial availability of the CosMx™ Human 6K ...

New liver tissue dataset highlights high sensitivity and specificity of CosMx system, and the biological power of spatially analyzing 1000 RNA targets NanoString Technologies, Inc. (NASDAQ: NSTG), a ...

That includes continuing to serve its customer base of researchers who use NanoString’s nCounter, GeoMx and CosMx platforms, which are used to spatially profile the RNA and certain protein ...

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, today announced the first commercial shipment of the CosMx™ Spatial Molecular ...

Wednesday, 10x Genomics Inc TXG won an injunction in its patent litigation against NanoString Technologies Inc NSTG and its German subsidiary regarding CosMx Spatial Molecular Imager instruments. ...

NanoString captured new orders for spatial biology instruments at a rate exceeding the Q1 pace and retained more than $30 million in the CosMx instrument order backlog.

Upcoming launch of CosMx 6,000-plex assay. NanoString also remains on track to begin commercial shipment of the CosMx Human 6K Discovery Panel beginning in Q1 2024.

The biotech company lost a patent court fight to 10x Genomics (TXG-0.15%) that forces NanoString to quit selling its CosMx Spatial Molecular Imager instruments and CosMx reagents for RNA detection ...